SHERBROOKE, Quebec--(BUSINESS WIRE)--Ulysses Pharma today announced the issuance of US Patent 7,410,974, covering its novel class of antibiotics which target drug resistant bacteria. The FQN class of antibiotics are designed to make the development of resistance almost impossible, because of their exquisite potency, rapid killing of bacteria and multiple mechanisms of action. This is the first in a series of patents covering the company’s technology to combat drug resistant bacteria.
